» Articles » PMID: 32178981

Integration of Lipidomics and Metabolomics for In-depth Understanding of Cellular Mechanism and Disease Progression

Overview
Publisher Science Press
Specialty Genetics
Date 2020 Mar 18
PMID 32178981
Citations 92
Authors
Affiliations
Soon will be listed here.
Abstract

Mass spectrometry (MS)-based omics technologies are now widely used to profile small molecules in multiple matrices to confer comprehensive snapshots of cellular metabolic phenotypes. The metabolomes of cells, tissues, and organisms comprise a variety of molecules including lipids, amino acids, sugars, organic acids, and so on. Metabolomics mainly focus on the hydrophilic classes, while lipidomics has emerged as an independent omics owing to the complexities of the organismal lipidomes. The potential roles of lipids and small metabolites in disease pathogenesis have been widely investigated in various human diseases, but system-level understanding is largely lacking, which could be partly attributed to the insufficiency in terms of metabolite coverage and quantitation accuracy in current analytical technologies. While scientists are continuously striving to develop high-coverage omics approaches, integration of metabolomics and lipidomics is becoming an emerging approach to mechanistic investigation. Integration of metabolome and lipidome offers a complete atlas of the metabolic landscape, enabling comprehensive network analysis to identify critical metabolic drivers in disease pathology, facilitating the study of interconnection between lipids and other metabolites in disease progression. In this review, we summarize omics-based findings on the roles of lipids and metabolites in the pathogenesis of selected major diseases threatening public health. We also discuss the advantages of integrating lipidomics and metabolomics for in-depth understanding of molecular mechanism in disease pathogenesis.

Citing Articles

Application of lipidomics in the study of traditional Chinese medicine.

Yang Y, Yang G, Zhang W, Xin L, Zhu J, Wang H J Pharm Anal. 2025; 15(2):101083.

PMID: 39995576 PMC: 11849089. DOI: 10.1016/j.jpha.2024.101083.


Role of plasma metabolome in mediating the effect of plasma lipidome on NAFLD: a Mendelian randomization study.

Zheng Z, Yang S, Dai W, Sun Y, Wang J, Zhang X Front Endocrinol (Lausanne). 2025; 15:1436827.

PMID: 39916753 PMC: 11798786. DOI: 10.3389/fendo.2024.1436827.


Lipidomics-based natural products for chronic kidney disease treatment.

Zhang R, Wang J, Wu C, Wang L, Liu P, Li P Heliyon. 2025; 11(1):e41620.

PMID: 39866478 PMC: 11758422. DOI: 10.1016/j.heliyon.2024.e41620.


Analysis of Key Differential Metabolites in Intervertebral Disc Degeneration Based on Untargeted Metabolomics.

Zhou D, Zhang X, Lv J, Mei Y, Luo Y, Li F JOR Spine. 2025; 8(1):e70032.

PMID: 39781087 PMC: 11707616. DOI: 10.1002/jsp2.70032.


Research on Lipidomic Profiling and Biomarker Identification for Osteonecrosis of the Femoral Head.

Yan Y, Wang J, Wang Y, Wu W, Chen W Biomedicines. 2025; 12(12.

PMID: 39767733 PMC: 11673004. DOI: 10.3390/biomedicines12122827.